Doxazosin Tablet
Product Images NDC 71610-482

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 71610-482). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 4 mg (71610 0482 60)

Doxazosin USP 2 mg oral tablets packaging label showing a 90-tablet count. The label includes storage instructions to keep between 20-25 degrees Celsius, dispensing guidelines to store in a tight light-resistant container, and warnings to keep the medication out of reach of children. The manufacturer is listed as Upsher-Smith Laboratories LLC in Maple Grove, MN, with packaging by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The label includes NDC 71610-0482-60 and barcodes for scanning.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Doxazosin 01)

Chemical structure diagram of the active ingredient Doxazosin Mesylate, showing its molecular arrangement and functional groups.*

FDA Label Image

Table 3 (Doxazosin 02)

A bar chart depicting results from two studies measuring symptom score and maximum flow rate (mL/sec) comparing placebo and Doxazosin doses. Study 2 shows significant improvement in maximum flow rate for 4 mg and 8 mg doses compared to placebo, along with symptom score reduction for 4 mg and 8 mg. The data highlights efficacy of Doxazosin mesylate tablets at these doses versus placebo.*

FDA Label Image

Figure 1 (Doxazosin 03)

Two line graphs showing clinical data for Doxazosin Tablets versus placebo over a 14-week treatment period. The left graph displays mean change in total symptom score from baseline, with larger decreases for Doxazosin. The right graph shows mean increase in maximum urinary flow rate (mL/sec) from baseline, with greater increases for Doxazosin. Both graphs indicate statistically significant differences favoring Doxazosin compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.